Integrated analysis of multidimensional genomic data on CALGB 40601 (Alliance), a randomized neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer

被引：2
|
作者：
Tanioka, M.
Fan, C.
Carey, L. A.
Hyslop, T.
Pitcher, B. N.
Parker, J. A.
Hoadley, K. A.
Henry, N. L.
Tolaney, S.
Dang, C.
Krop, I. E.
Harris, L.
Berry, D. A.
Mardis, E.
Perou, C. M.
Winer, E. P.
Hudis, C. A.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Duke Univ, Alliance Stat & Data Ctr, Durham, NC USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[6] NCI, Bethesda, MD 20892 USA
[7] Alliance Stat & Data Ctr MD Anderson, Houston, TX USA
[8] Washington Univ, St Louis, MO USA
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.SABCS16-S3-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S3-05
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A neoadjuvant, randomized, open-label phase II trial of afatinib (A) versus trastuzumab (T) versus lapatinib (L) in patients (pts) with locally advanced HER2-positive breast cancer (BC).
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Rozas, Ashley Alarcon
    Matos Neto, Joao Nunes
    Caleffi, Maira
    Vinholes, Jeferson J. F.
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina Maria
    Osborne, C. Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Neoadjuvant–adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
    Liang Huang
    Da Pang
    Hongjian Yang
    Wei Li
    Shusen Wang
    Shude Cui
    Ning Liao
    Yongsheng Wang
    Chuan Wang
    Yuan-Ching Chang
    Hwei-Chung Wang
    Seok Yun Kang
    Jae Hong Seo
    Kunwei Shen
    Suphawat Laohawiriyakamol
    Zefei Jiang
    Haiyan Wang
    François Lamour
    Grace Song
    Michelle Curran
    Chunzhe Duan
    Sanne Lysbet de Haas
    Eleonora Restuccia
    Zhimin Shao
    Nature Communications, 15
  • [33] Randomized phase II trial of preoperative lapatinib versus placebo in HER2-positive breast cancer
    De Censi, A.
    Puntoni, M.
    Pruneri, G.
    Guerrieri-Gonzaga, A.
    Cazzaniga, M.
    Johansson, H. A.
    Pala, O.
    Pagani, G.
    Brunenghi, M. Marre
    Bonanni, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] A Neoadjuvant, Randomized, Open-Label Phase II Trial of Afatinib Versus Trastuzumab Versus Lapatinib in Patients With Locally Advanced HER2-Positive Breast Cancer
    Rimawi, Mothaffar F.
    Aleixo, Sabina B.
    Alarcon Rozas, Ashley
    de Matos Neto, Joao Nunes
    Caleffi, Maira
    Figueira, Alicardo Cesar
    Souza, Sulene Cunha
    Reiriz, Andre B.
    Gutierrez, Carolina
    Arantes, Heloisa
    Uttenreuther-Fischer, Martina M.
    Solca, Flavio
    Osborne, C. Kent
    CLINICAL BREAST CANCER, 2015, 15 (02) : 101 - 109
  • [35] Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis
    Wang, Ruo-Xi
    Chen, Sheng
    Jin, Xi
    Chen, Can-Ming
    Shao, Zhi-Ming
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 161 (02) : 259 - 267
  • [36] Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis
    Ruo-Xi Wang
    Sheng Chen
    Xi Jin
    Can-Ming Chen
    Zhi-Ming Shao
    Breast Cancer Research and Treatment, 2017, 161 : 259 - 267
  • [37] A randomized trial of trastuzumab deruxtecan and biologydriven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE)
    Foukakis, T.
    Naume, B.
    Karakatsanis, A.
    Andersson, A.
    Barnekow, E.
    Kessler, L. Edman
    Einbeigi, Z.
    Engebraten, O.
    Killander, F.
    Linderholm, B. K.
    Schiza, A.
    Valachis, A.
    Bergh, J.
    Villacampa, G.
    Zouzos, A.
    Hellstrom, M.
    Hartman, J.
    Matikas, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S356 - S356
  • [38] A phase I clinical trial of entinostat and lapatinib in patients with trastuzumab refractory HER2-positive metastatic breast cancer
    Willey, Jie
    Alvarez, Ricardo H.
    Booser, Daniel J.
    Giordano, Sharon H.
    Gonzalez-Angulo, Ana M.
    Murray, James L.
    Valero, Vincente
    Lee, Jangsoon
    Ueno, Naoto T.
    Jackson, Summer A.
    Faruqi, Fahad A.
    CANCER RESEARCH, 2015, 75
  • [39] Tumor-infiltrating lymphocytes (TILs) in HER2-positive (HER2+) early breast cancer treated with neoadjuvant lapatinib and trastuzumab without chemotherapy in the PAMELA Trial
    Nuciforo, P.
    Prat, A.
    Llombart, A.
    Fasani, R.
    Pare, L.
    Pascual, T.
    Oliveira, M.
    Martinez Janez, N.
    Bermejo De las Heras, B.
    Vidal, M.
    Pernas Simon, S.
    Lopez, R.
    Munoz, M.
    Garau, I.
    Manso, L.
    Alarcon Company, J.
    Martinez de Duenas, E.
    Villagrasa Gonzalez, P.
    Cortes Castan, J.
    Holgado, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial
    Huang, Liang
    Pang, Da
    Yang, Hongjian
    Li, Wei
    Wang, Shusen
    Cui, Shude
    Liao, Ning
    Wang, Yongsheng
    Wang, Chuan
    Chang, Yuan-Ching
    Wang, Hwei-Chung
    Kang, Seok Yun
    Seo, Jae Hong
    Shen, Kunwei
    Laohawiriyakamol, Suphawat
    Jiang, Zefei
    Wang, Haiyan
    Lamour, Francois
    Song, Grace
    Curran, Michelle
    Duan, Chunzhe
    Lysbet de Haas, Sanne
    Restuccia, Eleonora
    Shao, Zhimin
    NATURE COMMUNICATIONS, 2024, 15 (01)
12345